What does VERZELE PHARMA do?

VERZELE PHARMA is a pharmacy in Oudenaarde. Private Limited, started on 28 March 2008, 1 establishment.

What is the address of VERZELE PHARMA?

The registered office of VERZELE PHARMA is located at Diependale 8, 9700 Oudenaarde.

Is VERZELE PHARMA still active?

Yes. According to the CBE (30 October 2026) VERZELE PHARMA is active, legal situation “Normale toestand”, started on 28 March 2008.

Is VERZELE PHARMA registered on Peppol?

Yes, VERZELE PHARMA is registered on the Peppol network with ID 0208:0896764703.

What is the enterprise number of VERZELE PHARMA?

The enterprise number of VERZELE PHARMA is BE0896764703.

When was VERZELE PHARMA founded?

VERZELE PHARMA was founded on 28 March 2008.

Who are the directors of VERZELE PHARMA?

According to the 2025 annual accounts, the directors of VERZELE PHARMA are: Philippe Verzele, Conrad Pharma BV.

Is VERZELE PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 March 2008; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did VERZELE PHARMA make in 2025?

VERZELE PHARMA posted a profit after taxes of € 38,414 in financial year 2025.

What is the revenue of VERZELE PHARMA?

As a small company, VERZELE PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 186,426.

How much does an employee at VERZELE PHARMA earn?

The average wage cost per full-time employee at VERZELE PHARMA was € 57,100 in 2025: staff costs of € 114,117 for 2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does VERZELE PHARMA have?

According to the 2025 annual accounts, VERZELE PHARMA has 2 full-time equivalents (FTE).

VERZELE PHARMA (Private Limited) - Oudenaarde

Dossier VERZELE PHARMA, printed on 30 October 2026 from databakkes.be/en/0896764703/verzele-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

VERZELE PHARMA from Oudenaarde, company number BE0896764703, closed financial year 2025 with a result of € 38,414 after tax. For that financial year VERZELE PHARMA recorded a gross margin of € 186,426 and equity of € 166,349. Compared with financial year 2024, the result moved from € 24,363 to € 38,414. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.

What it is worth Growing

€ 166,349

▲ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 38,414

▲ 58% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 169,128

▲ 3% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 28,000 paid out

73 % of the profit went to the shareholders, mostly to Conrad Pharma (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

▲ 0.7 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 114,117

▲ 7% vs 2024

€ 57,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 2,738

▼ 52% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 211,329

▼ 20% vs 2024

€ 54,393 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 52,804

▼ 14% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 33,965

▼ 7% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 233,240 Gross margin 2022: € 233,240 First fiscal year in the series	€ 218,749 Gross margin 2023: € 218,749 ▼ 6% vs 2022 (€ 233,240) Unfavourable step	€ 203,229 Gross margin 2024: € 203,229 ▼ 7% vs 2023 (€ 218,749) Unfavourable step	€ 186,426 Gross margin 2025: € 186,426 ▼ 8% vs 2024 (€ 203,229) Unfavourable step	▼ 8%
Profit after taxes	€ 64,887 Profit after taxes 2022: € 64,887 First fiscal year in the series	€ 38,424 Profit after taxes 2023: € 38,424 ▼ 41% vs 2022 (€ 64,887) Unfavourable step	€ 24,363 Profit after taxes 2024: € 24,363 ▼ 37% vs 2023 (€ 38,424) Unfavourable step	€ 38,414 Profit after taxes 2025: € 38,414 ▲ 58% vs 2024 (€ 24,363) Favourable step	▲ 58%
Equity	€ 147,149 Equity 2022: € 147,149 First fiscal year in the series	€ 155,573 Equity 2023: € 155,573 ▲ 6% vs 2022 (€ 147,149) Favourable step	€ 155,935 Equity 2024: € 155,935 Unchanged (€ 155,573) Favourable step	€ 166,349 Equity 2025: € 166,349 ▲ 7% vs 2024 (€ 155,935) Favourable step	▲ 7%
Total debts	€ 489,000 Total debts 2022: € 489,000 First fiscal year in the series	€ 485,144 Total debts 2023: € 485,144 ▼ 1% vs 2022 (€ 489,000) Favourable step	€ 394,923 Total debts 2024: € 394,923 ▼ 19% vs 2023 (€ 485,144) Favourable step	€ 334,248 Total debts 2025: € 334,248 ▼ 15% vs 2024 (€ 394,923) Favourable step	▼ 15%
Cash	€ 105,219 Cash 2022: € 105,219 First fiscal year in the series	€ 148,949 Cash 2023: € 148,949 ▲ 42% vs 2022 (€ 105,219) Favourable step	€ 163,566 Cash 2024: € 163,566 ▲ 10% vs 2023 (€ 148,949) Favourable step	€ 169,128 Cash 2025: € 169,128 ▲ 3% vs 2024 (€ 163,566) Favourable step	▲ 3%
Land & buildings	€ 164,459 Land & buildings 2022: € 164,459 First fiscal year in the series	€ 141,203 Land & buildings 2023: € 141,203 ▼ 14% vs 2022 (€ 164,459) Unchanged	€ 117,946 Land & buildings 2024: € 117,946 ▼ 16% vs 2023 (€ 141,203) Unchanged	€ 98,394 Land & buildings 2025: € 98,394 ▼ 17% vs 2024 (€ 117,946) Unchanged	▼ 17%
Retained profit	€ 128,549 Retained profit 2022: € 128,549 First fiscal year in the series	€ 136,973 Retained profit 2023: € 136,973 ▲ 7% vs 2022 (€ 128,549) Favourable step	€ 137,335 Retained profit 2024: € 137,335 Unchanged (€ 136,973) Favourable step	€ 147,749 Retained profit 2025: € 147,749 ▲ 8% vs 2024 (€ 137,335) Favourable step	▲ 8%
Dividend	€ 36,000 Dividend 2022: € 36,000 First fiscal year in the series	€ 30,000 Dividend 2023: € 30,000 ▼ 17% vs 2022 (€ 36,000) Unchanged	€ 24,000 Dividend 2024: € 24,000 ▼ 20% vs 2023 (€ 30,000) Unchanged	€ 28,000 Dividend 2025: € 28,000 ▲ 17% vs 2024 (€ 24,000) Unchanged	▲ 17%
Bank debt	€ 369,885 Bank debt 2022: € 369,885 First fiscal year in the series	€ 317,792 Bank debt 2023: € 317,792 ▼ 14% vs 2022 (€ 369,885) Favourable step	€ 264,944 Bank debt 2024: € 264,944 ▼ 17% vs 2023 (€ 317,792) Favourable step	€ 211,329 Bank debt 2025: € 211,329 ▼ 20% vs 2024 (€ 264,944) Favourable step	▼ 20%
Balance sheet total	€ 636,149 Balance sheet total 2022: € 636,149 First fiscal year in the series	€ 640,717 Balance sheet total 2023: € 640,717 ▲ 1% vs 2022 (€ 636,149) Unchanged	€ 550,859 Balance sheet total 2024: € 550,859 ▼ 14% vs 2023 (€ 640,717) Unchanged	€ 500,597 Balance sheet total 2025: € 500,597 ▼ 9% vs 2024 (€ 550,859) Unchanged	▼ 9%
Employees (FTE)	2 Employees (FTE) 2022: 2 First fiscal year in the series	2 Employees (FTE) 2023: 2 Unchanged (2) Unchanged	1.3 Employees (FTE) 2024: 1.3 ▼ 0.7 vs 2023 (2) Unchanged	2 Employees (FTE) 2025: 2 ▲ 0.7 vs 2024 (1.3) Unchanged	▲ 0.7

Key figures of VERZELE PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to VERZELE PHARMA?

What happened at VERZELE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 28, 2026 New annual accounts for financial year 2025: profit of € 38,414 (▲ 58% vs 2024). filed late Source: NBB ↗
Mar 28, 2008 New establishment in Kluisbergen. KBO
Mar 28, 2008 Start of the company according to the CBE. KBO

In short

From € 64,887 profit in 2022 to € 38,414 profit in 2025.

Paid € 41,719 in corporate taxes since 2022.

Best year ever: 2022, with € 64,887 profit.

On average € 93,200 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Conrad Pharma 100%

The stake of Conrad Pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

VERZELE PHARMA

Behind VERZELE PHARMA are Philippe Verzele and Conrad Pharma BV. The shares are held by Conrad Pharma (100%).

Directors

According to the 2025 annual accounts

Philippe Verzele

Director

Also active at: GEVA PHARMA, VERZELE PHARMA ZWALM, Conrad Pharma, DECAPHAR

Conrad Pharma BV

Director · represented by Vanessa Pluym

Also active at: GEVA PHARMA, VERZELE PHARMA ZWALM, DECAPHAR

Shareholders

Conrad Pharma

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Diependale 8

9700 Oudenaarde

2.170.183.176

Stationsstraat 28

9690 Kluisbergen

Active since 28 March 2008

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

GEVA PHARMA same network

€ 229,726 gross margin · 2025

VERZELE PHARMA ZWALM same network

€ 76,445 gross margin · 2025

Conrad Pharma same network

€ 504,793 gross margin · 2025

DECAPHAR same network

€ 300,895 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0896.764.703
VAT number: BE 0896.764.703
Registered office: Diependale 8, 9700 Oudenaarde
Names & denominations: VERZELE PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 28 March 2008
Peppol: Active · Active since 19 Nov 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗